David A. Roth

Nephrology

1801 NW 9th Ave
Miami, FL 33136

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 131 publications

Hematochezia : when should we worry ?

Hematochezia : when should we worry ?

Journal: Revue medicale suisse

Published: November 20, 2025

Comparison of Rifampin and Isoniazid for Latent Tuberculosis Infection in Kidney Transplant Candidates: Focus on Tolerability and Treatment Completion.

Comparison of Rifampin and Isoniazid for Latent Tuberculosis Infection in Kidney Transplant Candidates: Focus on Tolerability and Treatment Completion.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: October 16, 2025

Trends of preemptive kidney transplantation in lupus compared to other primary diseases leading to end stage kidney disease in the United States of America.

Trends of preemptive kidney transplantation in lupus compared to other primary diseases leading to end stage kidney disease in the United States of America.

Journal: Lupus

Published: May 20, 2025

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.

Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney response to belimumab in lupus nephritis.

Journal: Kidney international

Published: May 14, 2025

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Journal: Blood advances

Published: February 24, 2025

A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.

A pharmacokinetic and safety study of oral arsenic trioxide in patients with acute promyelocytic leukemia.

Journal: Blood advances

Published: November 25, 2024

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE study.

Journal: Annals of the rheumatic diseases

Published: February 16, 2024

Transplantation: platform to study recurrence of disease.

Transplantation: platform to study recurrence of disease.

Journal: Frontiers in immunology

Published: December 11, 2023

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Journal: Rheumatology (Oxford, England)

Published: December 01, 2023

Long-term effects of average calcineurin inhibitor trough levels (over time) on renal function in a prospectively followed cohort of 150 kidney transplant recipients.

Long-term effects of average calcineurin inhibitor trough levels (over time) on renal function in a prospectively followed cohort of 150 kidney transplant recipients.

Journal: Clinical and translational science

Published: August 28, 2023

Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.

Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression.

Journal: Leukemia & lymphoma

Published: August 12, 2023

The podocyte: glomerular sentinel at the crossroads of innate and adaptive immunity.

The podocyte: glomerular sentinel at the crossroads of innate and adaptive immunity.

Journal: Frontiers in immunology

Published: April 06, 2023

Showing 1-12 of 131

Last Updated: 09/26/2026